Fri, Dec 19, 2014, 10:15 AM EST - U.S. Markets close in 5 hrs 45 mins

Recent

% | $
Quotes you view appear here for quick access.

NanoLogix Inc. Message Board

commishfree1 10 posts  |  Last Activity: Dec 17, 2014 12:01 PM Member since: Mar 15, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    About Done

    by badbilly12 Dec 16, 2014 10:20 AM
    commishfree1 commishfree1 Dec 17, 2014 12:01 PM Flag

    "Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that they have received their first manufacturing run of their homeopathic treatment for chronic pain in companion animals, Pet Pain-Away™. The Company also announced that they have begun shipping and many distributors have already received their first orders.
    "Most of the pain-relieving drugs currently available for both the human and animal markets have severe side effects that may include gastrointestinal difficulties, kidney issues and narcotic problems," commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "Pet Pain-Away is a revolutionary new product that promises to change the way we deal with pet pain. It is an easy to use oral gel that pets love and it has none of the side effects associated with other analgesics," he continued. "We also know that Americans are apt to spend more on their pets than themselves, especially in indications of comfort and pain. We are especially pleased with the reception from the distributors ..."

    Wonder if they have plans for human investor use.....to take when their stock has entered "House of Pain" land.

  • Reply to

    About Done

    by badbilly12 Dec 16, 2014 10:20 AM
    commishfree1 commishfree1 Dec 17, 2014 8:19 AM Flag

    Marketwired - Dec 4, 2014) - Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
    "We have had a very busy year at Nutra Pharma," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "2014 has been a watershed year for the company, bringing in our first significant sales in three years, launching our first new product in over two years (Pet Pain-Away) and allowing us to begin the first steps to get back into clinical research on our lead drug candidates," he continued. "I wanted to take this opportunity to update our shareholders and the public on the accomplishments of the year, the status of the Company and briefly outline our goals and expectations for the coming months," he concluded."

    Remember these guys?.....How can you have a "watershed" year and a "busy year" and after all that your stock trades at .005/share? I guess when your share price value has "gone to the dogs", you're in need of "pet Pain-Away."

  • Reply to

    About Done

    by badbilly12 Dec 16, 2014 10:20 AM
    commishfree1 commishfree1 Dec 16, 2014 10:47 AM Flag

    BadBilly--" I honestly don't know what has happened here"

    Sounds like your take home message...in brief. LOL

  • Reply to

    Financials

    by leearlene1 Dec 15, 2014 12:40 PM
    commishfree1 commishfree1 Dec 16, 2014 9:53 AM Flag

    "Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, today announced it has initiated a clinical trial for its sample-to-result Staph ID/R (identification/resistance) diagnostic test. This is the second clinical trial the Company has initiated since July 2014 and, upon submission and if granted 510(k) clearance by the U.S. Food and Drug Administration (FDA), Staph ID/R will be Great Basin's third molecular diagnostic assay. In November of this year, the Company submitted its Group B Strep assay to FDA for 510(k) clearance. In 2012 the Company launched its FDA-cleared Toxigenic C. diff assay.
    Further, the Company announced that it has added two additional tests, a fungal panel and a test for Shiga toxin-producing E. coli (STEC) infections, to its clinical trial roadmap for 2015.
    "Great Basin continues to make effective use of the funds raised in our recent IPO, which have allowed us to initiate the clinical trial for Staph ID/R several months ahead of schedule," said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin. "Further, better-than-expected progress in R&D has expedited our ability to move products into clinical trials sooner than anticipated. Great Basin's technology uniquely allows us to provide both low-cost, low-plex tests and high-value, multi-plex panels, a real competitive advantage. Staph ID/R will be the first of many multi-plex panels we intend to bring to market which, we believe, offer significant cost advantages and ease-of-implementation and will provide improved patient care for the small-to-medium hospitals we serve."

    Hey Ray, here is an interesting comparison for you. NNLX at .05/share or GBSN at $2.50/share. Let's see you change up your "pathetic blather" and explain the disparity between the two small companies. Ya follow?

  • Reply to

    New quality document

    by rayludwiczak Dec 14, 2014 8:40 PM
    commishfree1 commishfree1 Dec 15, 2014 5:15 PM Flag

    So which number for "cash and cash equivalents" should we go with....the one I pointed out on the 1st page, or the one you pointed out on page 6?

  • Reply to

    New quality document

    by rayludwiczak Dec 14, 2014 8:40 PM
    commishfree1 commishfree1 Dec 15, 2014 3:18 PM Flag

    Cash and cash equivalents -- 1st qtr 3/31/2014
    $4,133

  • Reply to

    New quality document

    by rayludwiczak Dec 14, 2014 8:40 PM
    commishfree1 commishfree1 Dec 15, 2014 1:21 PM Flag

    Are you talking strictly about cash "resources"? They had $4133 in cash at the end of the 1st qtr.

  • Reply to

    So much for the short lived Ebola Hype....

    by smittensday Dec 1, 2014 4:34 PM
    commishfree1 commishfree1 Dec 10, 2014 8:51 AM Flag

    Last week--"Ceres Nanosciences Inc. (Ceres) today announced the commencement of a development program, funded by the Gates Foundation, to use Ceres' Nanotrap® particle technology to develop a new method of detecting the presence of the Ebola virus in saliva. During the four-month performance of this program, Ceres will work in close collaboration with George Mason University and the United States Army Medical Research Institutes of Infectious Diseases (USAMRIID) to assess the ability of the Nanotrap technology to develop a more sensitive and safer Ebola virus detection method that uses saliva instead of blood.
    Ceres, a biotechnology company located in Northern Virginia, has developed and commercialized a novel nanoparticle technology, the Nanotrap®, which provides powerful biofluid sample processing capabilities for a wide array of diagnostic applications and sample handling needs.
    The Nanotrap technology was invented at George Mason under funding from the National Institutes of Health (NIH) for biomarker discovery applications and is being developed into commercial products by Ceres with continuing support from NIH, Defense Advanced Research Projects Agency, the Department of Homeland Security and the Commonwealth of Virginia.
    The combined team of Ceres, Mason and USAMRIID will bring forward world-class research capabilities and resources to execute this project on a rapid schedule to address the dire need for better testing methods for Ebola."

    Looks like somebody took a good name first...the Nanotrap!!

  • Reply to

    happy holidays....it's over....

    by james997 Dec 4, 2014 4:37 PM
    commishfree1 commishfree1 Dec 5, 2014 7:32 AM Flag

    Well Bob, financials were released and for 2013 a net loss of $1.29 million was posted. How could you have made the statement they have "become profitable"? At the time of your post the stock was @ .15 or .16/share...it has managed to shed 75% of it's value....how do you reconcile "the price will be much higher."?
    All are anxiously waiting for your reply.

  • Reply to

    happy holidays....it's over....

    by james997 Dec 4, 2014 4:37 PM
    commishfree1 commishfree1 Dec 5, 2014 7:01 AM Flag

    RC (Rarely Correct) Bob 14 months ago -- "So, they have increased production workers at least 200%, extended the work week from 5 to 7 days, become profitable, but there is no demand. Nano, on wall street the early bird gets the worm, by the time financials are released, the price will be much higher. Then you can get in.. I am fine with my sources and my investment.. You and con should read Machiavelli10, now there is a guy, that is eloquent, factual and can connect the dots unlike you two. Bob"

    Is that you Bob...still riding the "uptrend"?

NNLX
0.03510.0000(0.00%)9:51 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.